AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence

Philippa Corrw; Andrea Marshall; Madusha Goonewardena; Janet A. Dunn; Mark R. Middleton; Paul D. Nathan; Martin Eric Gore; Neville Davidson; Steve Nicholson; Char Es G. Kelly; Maria Marples; Sarah Damson; Ernest Marshall; Stephen Houston; Ruth E. Board; Ashita Marie Waterston; Jenny Nobes; Mark Harries; Jim Barber; Paul Lorigan

AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence

Philippa Corrw, Andrea Marshall, Madusha Goonewardena, Janet A. Dunn, Mark R. Middleton, Paul D. Nathan, Martin Eric Gore, Neville Davidson, Steve Nicholson, Char Es G. Kelly, Maria Marples, Sarah Damson, Ernest Marshall, Stephen Houston, Ruth E. Board, Ashita Marie Waterston, Jenny Nobes, Mark Harries, Jim Barber, Paul Lorigan

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	Undefined
Article number	LBA9000
Journal	Journal of Clinical Oncology
Volume	31
Issue number	15/ Supplement
Publication status	Published - 20 May 2013
Event	49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Illinois, United States Duration: 31 May 2013 → 4 Jun 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Corrw, P., Marshall, A., Goonewardena, M., Dunn, J. A., Middleton, M. R., Nathan, P. D., Gore, M. E., Davidson, N., Nicholson, S., Kelly, C. E. G., Marples, M., Damson, S., Marshall, E., Houston, S., Board, R. E., Waterston, A. M., Nobes, J., Harries, M., Barber, J., & Lorigan, P. (2013). AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence. Journal of Clinical Oncology, 31(15/ Supplement), Article LBA9000.

@article{6a5120242bf143de97362c8687f4b585,

title = "AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence",

author = "Philippa Corrw and Andrea Marshall and Madusha Goonewardena and Dunn, {Janet A.} and Middleton, {Mark R.} and Nathan, {Paul D.} and Gore, {Martin Eric} and Neville Davidson and Steve Nicholson and Kelly, {Char Es G.} and Maria Marples and Sarah Damson and Ernest Marshall and Stephen Houston and Board, {Ruth E.} and Waterston, {Ashita Marie} and Jenny Nobes and Mark Harries and Jim Barber and Paul Lorigan",

year = "2013",

month = may,

day = "20",

language = "Undefined",

volume = "31",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "15/ Supplement",

note = "49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) ; Conference date: 31-05-2013 Through 04-06-2013",

}

Corrw, P, Marshall, A, Goonewardena, M, Dunn, JA, Middleton, MR, Nathan, PD, Gore, ME, Davidson, N, Nicholson, S, Kelly, CEG, Marples, M, Damson, S, Marshall, E, Houston, S, Board, RE, Waterston, AM, Nobes, J, Harries, M, Barber, J & Lorigan, P 2013, 'AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence', Journal of Clinical Oncology, vol. 31, no. 15/ Supplement, LBA9000.

TY - JOUR

T1 - AVAST-M

T2 - 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

AU - Corrw, Philippa

AU - Marshall, Andrea

AU - Goonewardena, Madusha

AU - Dunn, Janet A.

AU - Middleton, Mark R.

AU - Nathan, Paul D.

AU - Gore, Martin Eric

AU - Davidson, Neville

AU - Nicholson, Steve

AU - Kelly, Char Es G.

AU - Marples, Maria

AU - Damson, Sarah

AU - Marshall, Ernest

AU - Houston, Stephen

AU - Board, Ruth E.

AU - Waterston, Ashita Marie

AU - Nobes, Jenny

AU - Harries, Mark

AU - Barber, Jim

AU - Lorigan, Paul

PY - 2013/5/20

Y1 - 2013/5/20

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000335419605352&KeyUID=WOS:000335419605352

M3 - Meeting Abstract

SN - 0732-183X

VL - 31

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15/ Supplement

M1 - LBA9000

Y2 - 31 May 2013 through 4 June 2013

ER -

AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence

UN SDGs

Other files and links

Cite this